scholarly journals A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age

2015 ◽  
Vol 170 (3) ◽  
pp. 349-355 ◽  
Author(s):  
Sarah A. Buckley ◽  
Raya Mawad ◽  
Ted A. Gooley ◽  
Pamela S. Becker ◽  
Vicky Sandhu ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Phase I ◽  
Myeloid Leukaemia ◽  
Low Dose ◽  
Previously Treated ◽  
Low Dose Cytarabine ◽  
Acute Myeloid

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high‐risk myelodysplastic syndrome

2019 ◽  
Vol 102 (3) ◽  
pp. 218-226
Author(s):  
Marie Warny ◽  
Jens Helby ◽  
Henrik Sengeløv ◽  
Børge G. Nordestgaard ◽  
Henrik Birgens ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Telomere Length ◽  
Mononuclear Cell ◽  
Bone Marrow Mononuclear Cell ◽  
Acute Myeloid

scholarly journals Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia ◽  
2018 ◽  
Vol 33 (2) ◽  
pp. 379-389 ◽  
Author(s):  
Jorge E. Cortes ◽  
Florian H. Heidel ◽  
Andrzej Hellmann ◽  
Walter Fiedler ◽  
B. Douglas Smith ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Newly Diagnosed ◽  
Low Dose Cytarabine ◽  
Acute Myeloid

VERY-LOW-DOSE CYTARABINE FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA IN THE ELDERLY

The Lancet ◽  
1986 ◽  
Vol 327 (8487) ◽  
pp. 966 ◽  
Author(s):  
Alison Worsley ◽  
G.J. Mufti ◽  
J.A. Copplestone ◽  
D.G. Oscier ◽  
T.J. Hamblin
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Myelodysplastic Syndromes ◽  
Low Dose ◽  
The Elderly ◽  
Low Dose Cytarabine ◽  
Acute Myeloid

Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 6564-6564 ◽  
Author(s):  
D. A. Macdonald ◽  
S. E. Assouline ◽  
J. Brandwein ◽  
S. Kamel-Reid ◽  
E. A. Eisenhauer ◽  
...  
Keyword(s):  
High Risk ◽  
Elderly Patients ◽  
Myelodysplastic Syndrome ◽  
Phase I ◽  
Low Dose ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Low Dose Cytarabine
Sign in / Sign up

Export Citation Format

Share Document